We previously speculated that the difference in sensitivity between CML and normal progenitors to knockdown of PSMD1 or PSMD3 may be due to differences in post-translational modifications, which could alter peptide targets in malignant versus normal tissues [31]. This evidence concerns the gene PSMD3 and chronic myelogenous leukemia, BCR-ABL1 positive.